Immunogenic cell death inducers and PD-1 blockade as neoadjuvant therapy for rectal cancer

Abstract

Immuno-oncological cancer management is shifting to neoadjuvant treatments. In patients with gastrointestinal cancers, particularly locally advanced rectal cancer, neoadjuvant chemoimmunotherapy often induce complete responses, hence avoiding surgical intervention. Recent clinical trials indicate that combinations of oxaliplatin-based chemotherapy and PD-1/PD-L1-targeting immunotherapy can be safely administered before surgery with curative intent.

Keywords

• Cancer immunotherapy
• Immunogenic cell death
• Fc receptor
• Immune checkpoint inhibitor
• Total neoadjuvant therapy